Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
Authors
Keywords
Hepatocellular carcinoma, Biomodulatory therapy, COX-2 inhibitor, Pioglitazone, Metronomic low-dose chemotherapy, Anakoinosis
Journal
MEDICAL ONCOLOGY
Volume 34, Issue 12, Pages -
Publisher
Springer Nature
Online
2017-11-02
DOI
10.1007/s12032-017-1040-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
- (2017) Masatoshi Kudo ONCOLOGY
- Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
- (2016) Eirini Biziota et al. ANTI-CANCER DRUGS
- Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis
- (2016) Guodong Chen et al. Archives of Medical Science
- Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression
- (2015) Liang-qi Cao et al. CANCER LETTERS
- MiR-429 increases the metastatic capability of HCC via regulating classic Wnt pathway rather than epithelial–mesenchymal transition
- (2015) Jing Tang et al. CANCER LETTERS
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN
- (2015) Tian-Huei Chu et al. Oncotarget
- Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway
- (2015) Ning Zhang et al. Oncotarget
- Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study
- (2014) Milena Sant et al. LANCET ONCOLOGY
- Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma
- (2014) Takuji Torimura et al. Translational Oncology
- Prognostic Role of C-Reactive Protein in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
- (2013) Zhiyun Zheng et al. International Journal of Medical Sciences
- Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
- (2013) G. Brandi et al. ONCOLOGIST
- PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
- (2012) B Shen et al. BRITISH JOURNAL OF CANCER
- CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth
- (2012) Kin-Fai Cheung et al. CANCER
- Tumor size of hepatocellular carcinoma in noncirrhotic liver: A controversial predictive factor for outcome after resection
- (2012) S. Truant et al. EJSO
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular carcinoma with extrahepatic metastasis
- (2011) Koji Uchino et al. CANCER
- Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats
- (2011) Zheng Wang et al. Hepatobiliary & Pancreatic Diseases International
- Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro
- (2010) Jun Yu et al. HEPATOLOGY
- Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway
- (2009) Liang-qi Cao et al. ACTA PHARMACOLOGICA SINICA
- Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
- (2009) Puneeta Tandon et al. LIVER INTERNATIONAL
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started